Andexanet alfa

Drug Profile

Andexanet alfa

Alternative Names: AndexXa; AnXa; IndexXa; PRT-064445; PRT-4445; PRT-44545; Recombinant factor-Xa-Portola; rfXa-inhibitor-antidote

Latest Information Update: 22 Mar 2017

Price : $50

At a glance

  • Originator Portola Pharmaceuticals
  • Class Antidotes; Antihaemorrhagics; Disulfides; Recombinant proteins
  • Mechanism of Action Blood coagulation stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemorrhage
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Haemorrhage

Most Recent Events

  • 26 Feb 2017 Portola Pharmaceuticals initiates enrolment in a phase I trial in Healthy volunteers USA (NCT03083704)
  • 03 Dec 2016 Efficacy data from a phase II trial in Haemorrhage presented at the 58th Annual Meeting and Exposition of the American Society of Hematology (ASH-2016)
  • 03 Dec 2016 Pharmacodynamics data from preclinical studies in Haemorrhage presented at the 58th Annual Meeting and Exposition of the American Society of Haematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top